Trials / Terminated
TerminatedNCT03993613
Apotransferrin in Patients With β-thalassemia
Efficacy and Safety of Human Apotransferrin in Patients With β-thalassemia Intermedia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Prothya Biosolutions · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the trial is to study the effect of apotransferrin administration in patients suffering from β-thalassemia intermedia in order to restore the erythropoiesis as reflected by enhanced haemoglobin levels or reduced transfusion dependency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | human apotransferrin | Intravenous infusions |
Timeline
- Start date
- 2019-03-21
- Primary completion
- 2022-03-31
- Completion
- 2022-03-31
- First posted
- 2019-06-20
- Last updated
- 2022-08-15
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03993613. Inclusion in this directory is not an endorsement.